The event will focus on the therapeutic potential of VYNE’s novel and proprietary InhiBET^TM platform of its bromodomain and extra-terminal (BET) inhibitors, which includes a locally administered pan-BD BET inhibitor (VYN201) and an oral BD2-selective BET inhibitor (VYN202).

VYNE management will review the final results from the Phase 1b trial for VYN201 in patients with nonsegmental vitiligo and the event will also feature a presentation from Dr. Amit Pandya, former President of the Global Vitiligo Foundation and Staff Dermatologist, Department of Dermatology, Palo Alto Foundation Medical Group.

VYNE management will also review the preclinical data for VYN202 in psoriasis and rheumatoid arthritis and discuss its development plans for VYN201 and for VYN202.

A live question and answer session will follow the formal presentation.